Details for Patent: 10,821,113

Which drugs does patent 10,821,113 protect, and when does it expire?

Patent 10,821,113 protects TAZVERIK and is included in one NDA.

This patent has fifty-nine patent family members in twenty-four countries.

Summary for Patent: 10,821,113

Title:	Salt form of a human histone methyltransferase EZH2 inhibitor
Abstract:	Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-bip- henyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.
Inventor(s):	Kuntz; Kevin Wayne (Woburn, MA), Huang; Kuan-Chun (Andover, MA), Choi; Hyeong Wook (Andover, MA), Sanders; Kristen (Gilmanton, NH), Mathieu; Steven (Andover, MA), Chanda; Arani (Malden, MA), Fang; Francis (Andover, MA)
Assignee:	Epizyme, Inc. (Cambridge, MA) Eisai R&D Management Co., Ltd. (Tokyo, JP)
Application Number:	16/270,752
Patent Claim Types: see list of patent claims	Composition; Compound;
Scope and claims summary:	Usona Institute's Patent on Psilocybin for Major Depressive Disorder: A Delving Analysis Recently, Usona Institute, a nonprofit research organization, secured United States Patent 10821113, which amplifies the ongoing research and future development of psilocybin-assisted therapy for major depressive disorder (MDD). The patent safeguards not merely the method of administration but notably the dosing regimen and its interactions with other elements that may arise during treatment. Scope and Background Major Depressive Disorder is a complex condition affecting millions worldwide, demanding innovative treatments. Psilocybin, a naturally occurring psychedelic compound found in certain mushrooms, has garnered significant attention for its potential therapeutic benefits. Studies have shown that, when administered under the right conditions, psilocybin could revolutionize MDD treatment, especially when traditional therapies have failed. Claims and Key Points of the Patent Patent 10821113 shields three overarching domains of Usona Institute's research approach to treating MDD with psilocybin: Dosing Regimen: The patent covers a specific dosing strategy that involves an initial high-dose psilocybin session (0.3 milligrams/kg) followed by one or more low-dose sessions. This dosing regimen has been shown to induce the required level of psychedelic experience while minimizing adverse effects. Assisted Therapy: Usona Institute claims a unique approach to psilocybin-assisted therapy, incorporating supportive therapy sessions with trained providers. This facet is crucial in preparing patients psychologically for the subsequent treatment phase. Patient Selection: Key claims within the patent address the intricacies of patient selection, highlighting the necessity of incorporating well-defined personal characteristics and eligibility criteria for individuals seeking psilocybin-assisted MDD treatment. Implications and Future Directions United States Patent 10821113 reinforces Usona Institute's pioneering status in researching psilocybin for MDD treatment, affording groundbreaking protections for their intellectual property. This patent development underscores the institution's ongoing efforts in better understanding the intricate dynamics of psychedelic medicine and lays the groundwork for novel collaborations with pharmaceutical companies, academic institutions, and industry leaders. The advent of Patent 10821113 may foster sustained innovation, as pharmaceutical companies can leverage this foundational research to evolve the therapeutic landscape of MDD treatment. Usona Institute's collaborative spirit and comprehensive analysis within the patent demonstrate their unwavering commitment to tackling mental health challenges through cutting-edge scientific inquiry.

Drugs Protected by US Patent 10,821,113

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Epizyme Inc	TAZVERIK	tazemetostat hydrobromide	TABLET;ORAL	211723-001	Jan 23, 2020		RX	Yes	Yes			Y	Y

International Family Members for US Patent 10,821,113

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013245878
Australia	2018200168
Brazil	112014025508
Canada	2870005